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BACKGROUND: Neurocardiac injury is a type of myocardial dysfunction associated 
with neurological insult to the brain and occurs in 31-48% of aneurysmal subarachnoid 
hemorrhage (aSAH) patients. Elevated cardiac troponin I (cTnI) is commonly used to diagnose 
neurocardiac injury and has been associated with poor outcomes after aSAH. Brain natriuretic 
peptide (BNP) is another marker of cardiac dysfunction, but is more often used to evaluate 
varying degrees of heart failure. The purpose of this study was to examine the relationship 
between BNP and a) neurocardiac injury severity as defined by cTnI level, b) noninvasive 
continuous cardiac output (NCCO) monitoring parameters, and c) outcomes in aSAH patients. 
 
METHODS: This descriptive longitudinal study enrolled 30 adult patients age < 75 years 
diagnosed with aSAH. Data collected for 14 days included BNP and cTnI levels, NCCO 
monitoring parameters, and outcomes (modified Rankin scale [mRS] and mortality) at hospital 
discharge and three months. Generalized estimating equations (GEE) were used to evaluate the 
longitudinal associations between BNP and cTnI, BNP and NCCO monitoring parameters within 
30 minutes of BNP determination, and BNP and outcomes. BNP and NCCO variables required 
log transformation due to non-normal distribution.  
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RESULTS: Elevated BNP was significantly associated with cTnI. For every 1 unit 
increase in log BNP, cTnI increased by 0.05 ng/ml (p = .001). BNP was also significantly 
associated with thoracic fluid content (p = .0003) but no other NCCO parameters. On 
multivariable analyses, significant associations were found between BNP and poor mRS. For 
every 1 unit log BNP, patients were 3.16 times more likely to have a poor mRS at discharge (p = 
.021) and 5.40 times more likely to have poor mRS at 3 months (p < .0001). 
  
CONCLUSIONS: There is a significant relationship between BNP, cTnI, and poor 
outcomes after aSAH. BNP may have utility as a marker of neurocardiac injury and outcomes 
after aSAH. 
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1.0  INTRODUCTION AND BACKGROUND  
Neurocardiac injury is a type of myocardial dysfunction associated with neurological insult to 
the brain. After aneurysmal subarachnoid hemorrhage (aSAH), neurocardiac injury occurs in 31–
48% of patients [1–3]. It is widely accepted that neurocardiac injury is caused by an acute release 
of catecholamines that results from elevated intracranial pressure post-hemorrhage [4–6]. 
Manifestations of neurocardiac injury often include cardiac arrhythmias, widened QT intervals, 
depressed cardiac output and ejection fraction on echocardiogram, and elevated serum cardiac 
troponin I (cTnI) [2]. Neurocardiac injury is typically diagnosed with elevated cTnI (≥ 0.3 
ng/mL) and myocardial wall motion abnormalities on echocardiogram within the first five days 
following aneurysm rupture [2, 3]. Elevated cTnI levels are seen in 20-68% of aSAH patients 
who have no prior history of cardiac disease or myocardial infarction [7–9]. In addition, elevated 
cTnI has been associated with poorer Hunt and Hess (HH) grade, Fisher grade, and neurological 
status on hospital admission [7–9]. Furthermore, elevated cTnI has been associated with 
increased risk for developing cardiopulmonary complications and delayed cerebral ischemia [7, 
10]. Therefore, it can be suggested that the degree of neurological insult is implicated in 
neurocardiac injury development. 
Demographic and prior comorbidity risk factors for neurocardiac injury include advanced 
age, coronary artery disease, hypertension, and other cardiovascular disorders [11]. Although 
neurocardiac injury after aSAH is often transient [4], evidence suggests that it is associated with 
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increased mortality [12]. In addition, neurocardiac injury is independently associated with poorer 
functional outcomes in aSAH patients [2, 13]. The reason for this association may be related to 
the impact of hypotension, arrhythmias, and depressed ejection fraction and stroke volume on 
cerebral blood flow [2, 14]. 
Brain natriuretic peptide (BNP) is a 32-amino acid peptide that is released in response to 
cardiac myocyte stretch due to elevated filling pressures [15], in order to regulate blood pressure 
and fluid balance [16]. BNP is produced by cardiac ventricular cardiomyocytes, as well as in the 
hypothalamus [17–19]. BNP is often used diagnostically during the evaluation of patients 
presenting with symptoms of acute dyspnea to determine whether their etiology is of a cardiac or 
pulmonary origin [20]. Meaudre et al reported that 25 patients (80%) diagnosed with aSAH had a 
BNP level greater than 100 ng/L during the first three days after aneurysm rupture, whereas by 
the seventh day, only 4 patients (13%) remained elevated above 100 ng/L [15]. A significant 
association has also been reported between BNP, cTnI, cardiac dysfunction measured by 
transthoracic echocardiogram (regional wall motion abnormalities, reduced left ventricular 
function, and diastolic dysfunction) and the development of pulmonary edema after aSAH [20]. 
Tung et al also found increased BNP levels to be significantly associated with increased inpatient 
mortality in aSAH patients who had no prior history of myocardial infarction or congestive heart 
failure [21]. 
Based on the current literature, the degree to which BNP level correlates with the severity 
of neurocardiac injury, cardiac output, and functional outcomes after aSAH is not well 
established. It also remains unclear if BNP level can be used as an independent predictor of 
neurocardiac injury in this population. Although BNP is known to be associated with cardiac 
dysfunction according to echocardiogram, it would also be helpful to determine if there is a 
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relationship between BNP and noninvasive continuous cardiac output (NCCO) parameters. 
Determining the relationship between BNP, NCCO, and functional outcomes could potentially 
help to determine whether BNP could be used as a biomarker for neurocardiac injury and poor 
outcomes after aSAH. 
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2.0  PURPOSE AND AIMS 
The overarching purpose of this study is to examine the relationship between BNP and a) 
neurocardiac injury severity, b) noninvasive continuous cardiac output, and c) outcomes in aSAH 
patients. The specific aims of this study are to:  
Specific aim #1: Determine the relationship between BNP level and the degree of neurocardiac 
injury as defined by cTnI level.  
Specific aim #2: Examine the relationship between BNP level and noninvasive continuous 
cardiac output monitoring parameters.  
Specific aim #3: Assess the relationship between BNP level and outcomes (mortality, modified 
Rankin Scale [mRS]) at hospital discharge and 3 months after aSAH. 
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3.0  METHODS 
3.1 SAMPLE AND SETTING 
This is a descriptive longitudinal study of data collected prospectively on aSAH patients enrolled 
in an NIH funded study (R01NR014221). Patients between the ages of 21 and 75 years, admitted 
to the neurological intensive care unit (NICU) after being diagnosed with aSAH by computed 
tomography (CT) and/or cerebral angiogram and assigned a Fisher grade > 1 by the attending 
neurosurgeon were eligible. Patients were excluded if they had preexisting chronic neurological 
disease, traumatic subarachnoid hemorrhage, mycotic aneurysms, or myocardial infarction 
within the past year. Informed consent was obtained from all eligible patients based on an IRB 
approved protocol (021039). All aSAH inpatients received standard nursing and medical care in 
the NICU. 
3.2 STUDY VARIABLES 
3.2.1 Demographic and Clinical Characteristics 
Basic demographic information including severity of injury, aneurysm information, age, race, 
gender, and past medical history were obtained from the patient, family, or medical record. 
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Severity of injury (HH grade and Fisher grade) was obtained from the neurosurgical notes in the 
patient’s clinical record. The Hunt and Hess scale is used to grade the severity of non-traumatic 
SAH based on symptoms at presentation to the emergency department [22]. A higher score 
corresponds to a higher severity, and the scale has five grades; 1 = asymptomatic, or minimal 
headache and slight nuchal rigidity; 2 = moderate to severe headache, nuchal rigidity, no 
neurological deficit other than cranial nerve palsy; 3 = drowsiness, confusion, or mild focal 
deficit; 4 = stupor, moderate to severe hemiparesis, possibly early decerebrate rigidity and 
vegetative disturbances; and 5 = deep coma, decerebrate rigidity, moribund appearance [22]. The 
Fisher grade is used to classify the initial appearance of SAH based on CT scan findings [23]. 
The scale has four grades; 1 = no blood or hemorrhage evident; 2 = diffuse or thin layer of blood 
less than 1 mm thick (interhemispheric, insular, or ambient cisterns); 3 = localized clots and/or 
layers of blood greater than 1 mm thick in the vertical plane; 4 = intracerebral or intraventricular 
clots with diffuse or absent blood in basal cisterns [23]. 
3.2.2 BNP 
Blood samples were collected daily. BNP was measured by chemiluminescence on a Beckman 
Coulter Access analyzer (Beckman Instruments Inc., Chaska, MN) using the Lumi-Phos 530 
ready-to-use chemiluminescent reagent formulation containing alkaline phosphatase substrate, 
Lumigen PPD, at the hospital laboratory. The lower limit of analytical range for BNP was 1 
pg/ml; and the upper limit was 5000 pg/ml. 
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3.2.3 Neurocardiac Injury 
Neurocardiac injury was defined by cTnI level. cTnI was extracted from serum at least daily and 
quantified by a Beckman Coulter Access AccuTnI assay (Beckman Instruments Inc., Chaska, 
MN), a two-site immunoenzymatic assay that uses the chemiluminescent substrate Lumi-Phos 
530, at the hospital laboratory. The lower analytical limit for cTnI was 0.001 ng/ml, and the 
upper limit was 75 ng/ml. cTnI was used as a continuous variable. 
3.2.4 Cardiac Output Monitoring 
An FDA-approved NCCO device was used (NICOM®, Cheetah Medical, Wilmington, DE) to 
continuously record cardiac output measurements. The device’s function is based on 
transthoracic Bioreactance® monitoring that analyzes relative phase shifts of an oscillating 
current traversing the thorax surface. Continuously obtained data were downloaded on each 
patient at a minimum frequency of one data point every 30 seconds. In the analyses, NCCO data 
were averaged on 5-minute intervals. Variables collected through NCCO included cardiac output 
(CO), cardiac index (CI), stroke volume index (SVI), stroke volume variation (SVV), thoracic 
fluid content (TFC), ventricular ejection time (VET), cardiac contractility (dx/dt), and heart rate 
(HR). 
3.2.5 Outcomes 
Patient outcomes were assessed at discharge and at three months post-aSAH using the modified 
Rankin Scale (mRS). The mRS is a self-appraisal of functional disability containing mental and 
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physical adaptations [24]. It is widely used in stroke populations and contains seven levels; 0 = 
no symptoms at all; 1 = no significant disability despite symptoms;   2 = slight disability (unable 
to perform all activities); 3 = moderate disability (able to walk without assistance); 4 = 
moderately severe disability (unable to walk without assistance); 5 = severe disability 
(bedridden, incontinent, in nursing home) and 6 = death [24]. mRS at discharge was based on 
medical record information, while 3-month mRS was based on patient interviews. If subjects 
were unable to complete the interview, a family member or caregiver answered the questions. 
mRS was dichotomized as good (mRS 0-2) and poor (mRS 3-6). Inpatient records or family 
members provided information regarding patient mortality.  
3.3 ANALYTIC APPROACH 
To describe the sample, we used frequency distributions for categorical variables and mean and 
standard deviations for normally distributed continuous variables, or median and interquartile 
ranges for non-normally distributed continuous variables. IBM SPSS 22 and SAS 9.3 were used 
with a p-value of 0.05 or less indicating significance. Due to non-normal distribution of the data, 
logarithmic transformation was used for BNP in each analysis and for certain NCCO variables. 
The analysis plan for each specific aim is listed below. 
Specific aim #1: Determine the relationship between BNP level and degree of 
neurocardiac injury as defined by cTnI level.  
The levels of BNP and cTnI collected over the study period were included, and the daily peak 
values of each were used in the analysis as time-varying variables. Generalized estimating 
equation (GEE) was used to evaluate the longitudinal association between BNP and cTnI where 
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BNP was used as the independent variable and cTnI as the dependent variable without covariate 
adjustment. Logarithmic transformation of BNP was used. 
Specific aim #2: Examine the relationship between BNP level and continuous non-
invasive cardiac output monitoring parameters.  
The relationship between BNP and NCCO was analyzed using GEE. BNP was used as the 
independent variable. NCCO values were averaged over 5 minutes. For each BNP level (all data 
points used) the NCCO data for the 30 minutes before and after BNP determination (1 hour total) 
were used. Logarithmic transformation was used for BNP as well as for cardiac output, cardiac 
index, stroke volume, stroke volume index, thoracic fluid content, dx/dt, and ventricular ejection 
time. Therefore, the only two NCCO variables that were not log transformed were heart rate and 
stroke volume variation. 
Specific aim #3: Assess the relationship between BNP level and outcomes (mortality and 
mRS) at hospital discharge and at 3 months post-aSAH.  
In order to assess the relationship between BNP and outcomes, GEE was conducted. All BNP 
levels collected over the study period were included in the model as the independent variable, 
and mRS was treated as a categorical variable dichotomized as good and poor, as described. 
Mortality was included in the analysis as a dichotomous variable. Logarithmic transformation of 
BNP was used.   
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4.0  RESULTS 
A total of 30 patients were recruited in this study. As shown in Table 1, patients were 
predominantly female, middle aged, and Caucasian. The majority of patients had an admission 
HH grade of 2 (43%) or 3 (33%). Fourteen (53.3%) had poor mRS at discharge and similarly 
fourteen (48.3%) had poor mRS at 3 months post-hemorrhage. Four patients died by hospital 
discharge and one additional patient died by the follow-up at 3 months. One patient was lost to 
the 3-month follow-up. The daily mean cTnI was 0.20 ng/ml, with a minimum value of 0.04 
ng/ml and maximum value of 10.36 ng/ml. The daily mean BNP level was 322.99 pg/ml, and the 
minimum and maximum values ranged from 5.00 pg/ml to 2676.00 pg/ml respectively. The 
mean time of NCCO monitoring was 8.89 days, ranging from 1.05 to 13.70 days. 
Finding related to specific aim #1: Determine the relationship between BNP levels and 
the degree of neurocardiac injury as defined by cTnI level.  
GEE modeling on daily peak cTnI and daily peak BNP showed statistically significant 
association between cTnI and BNP. For every 1 unit increase in log BNP, cTnI increased by 0.05 
ng/ml (p = .001).  
Findings related to specific aim #2: Examine the relationship between BNP and 
continuous non-invasive cardiac output monitoring parameters.  
Table 2 shows the relationship between BNP and NCCO parameters without covariate 
adjustment. The results show that BNP increases by 0.09 pg/ml for every 1 unit increase in log 
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TFC (p = .0003). There was no statistically significant relationship between BNP and any other 
NCCO-derived variable.  
Finding related to specific aim #3: Assess the relationship between BNP and outcomes 
(mortality and mRS) at hospital discharge and at 3 months post-aSAH.  
On univariable analyses, there were significant association between log BNP and poor mRS at 3 
months, mortality at 3 months, and mortality at discharge. There was a trend toward significance 
for the association between log BNP and poor mRS at discharge. For every 1 unit increase in log 
BNP, patient were 1.26 and 4.90 times more likely to have poor mRS at discharge (p = .069) and 
at 3 months (p < .0001) respectively. Furthermore, for every 1 unit increase in log BNP, patients 
were 1.42 and 1.43 times more likely to die at discharge (p = .032) and at 3 months (p = .031) 
respectively. Similar results were found on multivariable analyses (Table 3). BNP remained a 
significant predictor for poor outcome even after controlling for age and HH grade. For every 1 
unit increase in log BNP, patients were 3.16 times more likely to have a poor outcome at 
discharge (p = .021) and 5.40 times more likely to have poor mRS at 3 months (p < .0001). For 
every 1 unit increase in age, patients were 3.18 times more likely to have a poor outcome at 
discharge (p < .0001), and 0.96 times more likely to have a poor outcome at 3 months post-
hemorrhage (p = .573). For every 1 unit increase in HH grade, patients were 86.29 times more 
likely to have a poor outcome at discharge (p = .019) and 6.53 times more likely to have a poor 
outcome at 3 months post-hemorrhage (p = .052).  
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5.0  DISCUSSION 
Our main finding corroborates that BNP increases as cTnI increases and, therefore, supports the 
use of BNP as a marker of neurocardiac injury. This relationship may be mediated by the known 
catecholamine surge that occurs after aneurysm rupture and that often results in myocardial 
dysfunction and subsequent neurocardiac injury [2]. In response to the injury, inflammation, and 
cardiac myocyte stretch, BNP is secreted and its levels gradually increase [15]. 
We also sought to assess the relationship between BNP and cardiac function based on a 
novel approach using NCCO. We were able to demonstrate that BNP increases as thoracic fluid 
content, a marker of pulmonary edema, increases. This finding is not surprising given the known 
relationship between BNP and increased myocardial stretch and wall tension [25]. Thoracic fluid 
content, as measured by NCCO, is a qualitative measure of directional changes in total thoracic 
fluid content [26, 27]. Therefore, as thoracic fluid volume increases, theoretically both 
myocardial stretch and wall tension will increase. Subsequently, BNP will be secreted, and BNP 
levels will continue to rise.  
Tung et al [8] found that elevated BNP levels are associated with myocardial necrosis, 
pulmonary edema, and left ventricular systolic and diastolic dysfunction early after SAH. 
However, we were unable to demonstrate that elevated BNP was significantly associated with 
depressed myocardial function by any variable measured with NCCO, with the exception of 
elevated thoracic fluid content. Possibly our sample size was too small to detect such a change, 
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and this is a study limitation. It is also possible that the use of vasopressors for blood pressure 
support in this population may have affected the NCCO parameters, which is also a significant 
limitation of the study. 
Yarlagadda et al [28] found BNP levels greater than 600 pg/ml to be a significant 
indicator of mortality after aSAH, while Duello et al [29] did not find any significant relationship 
between BNP elevation and increased mortality. We also were not able to demonstrate a 
relationship between BNP and mortality. We did find, however, that elevated BNP was 
associated with poorer mRS at discharge and 3 months later, and that this association was 
independent of age and HH grade. No other study to our knowledge has investigated the 
relationship between BNP and poor mRS in the aSAH population. Taub et al [30] found that 
elevated BNP levels are independently associated with cerebral infarction following aSAH. Sviri 
et al [31] reported that elevated BNP levels are related to severity of bleeding and vasospasm 
following aSAH. However, the mechanistic underpinning explaining these poorer outcomes for 
aSAH patients with elevated BNP is still unclear. McGirt et al [32] found that elevated BNP was 
independently associated with hyponatremia and predicted the 2-week Glasgow Coma Scale 
score. Thus, the pathophysiological mechanism linking elevated BNP and poorer functional 
outcomes remains unclear. Whether poor outcomes are an indirect result of elevated BNP levels 
or a direct result of alternative mechanisms still requires further investigation. Future studies 
must involve larger sample sizes and analysis of other potential variables. Once this further 
investigation is conducted, BNP may prove to be a valuable independent marker of neurocardiac 
injury. 
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6.0  CONCLUSION 
The clinical implications of this study relate to the significant relationship between BNP and 
cTnI, and that elevated BNP is associated with poor mRS in aSAH patients, even after age and 
injury severity are taken into account. If BNP levels are routinely monitored in aSAH patients, 
healthcare providers will be more aware of any increased likelihood of adverse outcomes that 
these patients may have. Therefore, the healthcare providers may be able to more promptly 
incorporate strategies into the patient’s plan of care that may help to prepare for or prevent such 
potential adverse outcomes. Overall, the establishment of BNP as a potential predictor of poor 
outcomes may promote a more effective, therapeutic approach to treating patients who have 
experienced aSAH. 
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Table 1 - Characteristics of patients in the sample (n=30) 
Characteristics  
 
Statistics  
Age in years (mean±SD) 
 
54.5 ± 11.1 
Admission GCS (mean±SD) 
 
12.3 ± 4.1 
Gender [n (%)] 
 Male 
 Female 
 
 
2 (6.7%) 
28 (93.3%) 
Race [n (%)] 
White 
Black 
 
 
28 (93.3%) 
2 (6.7%) 
Admission Hunt and Hess [n (%)] 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 
 
 
1 (3.3%) 
13 (43.3%) 
10 (33.3%) 
4 (13.3%) 
2 (6.7%) 
mRS at discharge [n (%)] 
Poor (mRS 3-6) 
Good (mRS 0-2) 
 
 
16 (53.3%) 
14 (46.7%) 
mRS at 3 months [n (%)] 
Poor (mRS 3-6) 
Good (mRS 0-2) 
 
 
14 (48.3%) 
15 (51.7%) 
Mortality at discharge [n (%)] 
Dead 
Alive 
 
 
4 (13.3%) 
26 (86.7%) 
Mortality at  3 months [n (%)] 
Dead  
Alive 
 
5 (17.24%) 
24 (82.76%) 
Key: GCS = Glasgow Coma Scale, mRS = modified Rankin Scale, SD = standard 
deviation  
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Table 2 - Relationship between patients (n=30) brain natriuretic peptide (BNP)  levels and 
noninvasive continuous cardiac output monitoring (NCCO) parameters for 30 minutes 
before and after each BNP measurement. 
NCCO Estimate Standard Error p-value 
log Cardiac Output 0.02 0.04 0.578 
log Cardiac Index 0.03 0.04 0.572 
Heart Rate -0.16 0.16 0.317 
log Stroke Volume 0.05 0.03 0.106 
log Stroke Volume Index 0.05 0.03 0.098 
Stroke Volume Variation -0.24 0.37 0.515 
log Thoracic Fluid Content 0.09 0.02 0.0003* 
log dx/dt 0.05 0.04 0.192 
log Ventricular Ejection Time 0.00 0.03 0.871 
Key: dx/dt = maximum aortic flow (indirect measure of contractility) 
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Table 3 - Multivariable analysis of the relationship between brain natriuretic peptide (BNP) and outcomes at hospital 
discharge and 3 months. 
Variable 
mRS at discharge 
n=30 
mRS at 3 months 
n=29 
Mortality at discharge 
n=30 
Mortality at 3 months 
n=29 
OR  95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Log BNP 3.16   (1.19, 8.39) .021* 5.40 (3.24, 8.99) <.0001* 1.30 (0.92, 1.84) .130 1.28 (0.90, 1.82) .175 
Age 3.18   (1.84, 5.51) <.0001* .96 (0.84, 1.10) .573 --  -- --  -- 
HH grade 86.29 (2.11, 3526.99) .019* 6.53 (0.98, 43.27) .052 1.69 (0.35, 8.24) .518 2.05 (0.45, 9.28) .352 
Key: mRS = modified Rankin Scale, HH = Hunt and Hess, OR = odds ratio, CI = confidence interval  
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